The total return over the past 12 months is -31.59% vs. +16.94% for the S&P 500. So far it's up -26.04% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (31.59%) | +0.89% | (25.30%) | N/A | N/A | N/A |
| Total Return CAGR | (31.59%) | +0.89% | (25.30%) | N/A | N/A | N/A |
| Revenue CAGR | +55.00% | N/A | (65.38%) | (40.47%) | (36.14%) | (17.51%) |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Altimmune, Inc. (ALT)
| Year | Start price | End price | ALT Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $3.61 | $2.67 | (26.04%) | +14.51% | (40.55%) |
| 2025 | $7.21 | $3.61 | (49.93%) | +17.72% | (67.65%) |
| 2024 | $11.25 | $7.21 | (35.91%) | +24.89% | (60.80%) |
| 2023 | $16.45 | $11.25 | (31.61%) | +26.19% | (57.80%) |
| 2022 | $9.16 | $16.45 | +79.59% | (18.17%) | +97.76% |
| 2021 | $11.28 | $9.16 | (18.79%) | +28.74% | (47.53%) |
| 2020 | $1.89 | $11.28 | +496.83% | +18.37% | +478.46% |
| 2019 | $2.06 | $1.89 | (8.25%) | +31.22% | (39.47%) |
| 2018 | $59.70 | $2.06 | (96.55%) | (4.56%) | (91.99%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
